Immuneering (IMRX) Income towards Parent Company (2020 - 2026)

Immuneering's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$32.1 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 110.46% year-over-year to -$32.1 million in Q1 2026; TTM through Mar 2026 was -$108.7 million, a 45.18% decrease from a year earlier, with the FY2025 full-year figure at -$129.7 million, down 7.67% from the prior year.
• Income towards Parent Company slipped to -$32.1 million in Q1 2026 per IMRX's latest filing, from -$12.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$12.1 million in Q4 2025 and bottomed at -$44.5 million in Q3 2025.
• The 5-year median for Income towards Parent Company is -$19.4 million (2022), against an average of -$22.3 million.
• Across the five-year window, Income towards Parent Company tumbled 188.98% in 2022 and surged 40.55% in 2024, its largest moves.
• Year by year, Income towards Parent Company stood at -$13.6 million in 2022, then fell by 15.75% to -$15.7 million in 2023, then fell by 16.43% to -$18.3 million in 2024, then jumped by 34.08% to -$12.1 million in 2025, then slumped by 165.32% to -$32.1 million in 2026.
• Per Business Quant, the three latest IMRX Income towards Parent Company figures stand at -$32.1 million (Q1 2026), -$12.1 million (Q4 2025), and -$44.5 million (Q3 2025).